Response to imatinib plus sirolimus in advanced chordoma.
about
UK guidelines for the management of bone sarcomasPaediatric ChordomasChordoma: clinical characteristics, management and prognosis of a case series of 25 patients.Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomasThe biological basis for modern treatment of chordoma.Unveiling the molecular pathogenesis of chordoma: a new paradigm for molecular targeting of rare cancers.Systemic therapy options for unresectable and metastatic chordomas.Recurrent chromosomal copy number alterations in sporadic chordomas.Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.Durable complete response to chemotherapy in an infant with a clival chordoma.Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.Current therapeutic options and novel molecular markers in skull base chordomas.Association of surgical resection and survival in patients with malignant primary osseous spinal neoplasms from the Surveillance, Epidemiology, and End Results (SEER) database.The evolution of systemic therapy in sarcoma.Phase II study on lapatinib in advanced EGFR-positive chordoma.From notochord formation to hereditary chordoma: the many roles of Brachyury.Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.Fractionated stereotactic radiosurgery treatment results for skull base chordomas.Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum.Multidisciplinary management of recurrent chordomas.Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.Sustained response of a clivus chordoma to erlotinib after imatinib failure.Novel targeted therapies in chordoma: an update.Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.Mutation Analysis of Nine Chordoma Specimens by Targeted Next-Generation Cancer Panel SequencingMultidisciplinary approach of lumbo-sacral chordoma: From oncological treatment to reconstructive surgery.Chordoma in children: Case-report and review of literature.A unique case of distant skin metastasis from chondroid chordomaDurable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFRSystemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.Reprint of "Chordoma in children: Case-report and review of literature"Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case seriesRecent advances in understanding and managing chordomas.Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma.Chordoma Occurs in Young Children With Tuberous Sclerosis.
P2860
Q26752425-71898619-9D8D-45D3-9E84-81986310B4E7Q26782622-B85ED129-D80B-454A-80C8-D345E54F82B3Q33273672-53595056-1D8C-4A83-B7FB-DF43A500FA82Q33273701-2467658E-94FF-4DFD-AE71-BD00754EE7F3Q33274086-D26FDC7E-3E45-4E31-9666-8D93171A5CA9Q33274088-BE0EC36C-6A35-431E-B596-D9E8CBA8E0AEQ33274146-728616E9-B83C-46B8-8889-12083710B594Q33274149-B45B25B6-7F18-4639-88AA-D852D23A1532Q33274171-E4BB9A57-D4A3-47FE-8653-71618D60CA2BQ33274237-236270A5-69E4-4E8F-A5EE-8BD9063749F0Q33274256-CCCC9E8E-9FEA-41C1-B663-BAB066F45B54Q33274278-F17B18BC-4C7F-4B55-9212-1C8AF202526DQ33274663-06D781FF-3C00-47CC-A62F-ADADFEDC9B0BQ33274710-11591427-CE40-4600-AB28-396C4A57445DQ33274760-23897176-E418-4E7B-9124-CE51258786FEQ33274793-EB29BC98-9E01-4A34-82CB-C904F0F018C4Q33274834-565CBFF7-5A64-4800-AF1E-D6A0BFDFF65EQ33274839-8271DAA1-E4EC-428A-86BB-90A2BAC99EABQ33274866-EE79B36A-5C16-4908-9AD5-8103B5736265Q33274875-F61DEFE8-1C6A-446D-8261-A3EA4E0DCA0FQ33274900-4252ABBB-5D94-4AA5-AFA0-4F9AB7C3A89BQ33275031-68BD38FB-CCA8-48F3-B4A9-D0C04158FBB6Q33275053-A37F2FB4-7B27-4F2C-B08B-F837D4A454CBQ33275064-9A1C70B7-397F-4E97-955A-EC5B556708EEQ33275402-60B66BDA-C48A-4A52-9AFE-30B5D6724F06Q33275576-CDDD99E2-498F-42F9-9BE5-24450F30C5CBQ33275653-FEAFF072-58E9-4D43-A685-933F51F30ACEQ33275671-B9D9A37B-E6E3-4F97-8FE3-179BAB8C0185Q33275749-6865A77A-645F-4467-AAAF-E3F629B28B29Q33275786-B0528834-C4DB-41D2-90FF-1BE07CCF42DBQ33275928-512AE733-147A-42F5-B8AB-DF6929698137Q33275970-50A0F6A8-C4AD-4D0E-9B73-B8DF1A908192Q33276057-57A73EB3-B5E8-412D-A8F1-4854964FE325Q33276109-1CA52DAE-FB07-4846-8D60-586F37A310FCQ33276114-AC91BC15-1B4E-453E-B4D5-B2A35F95A298Q33276267-F7053B8F-5A3B-44DB-821C-269408D6BF6DQ33276348-F0624DCF-05F7-4D53-930D-7385EAB3B3FDQ33276384-7B46E196-4F05-4819-BBAE-84008F5412A5Q33276468-FA76A8EB-3DCC-4AFD-8D1A-DD3E7AB66253Q33276501-E7A97440-8B81-431E-9754-F99B4F66E963
P2860
Response to imatinib plus sirolimus in advanced chordoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Response to imatinib plus sirolimus in advanced chordoma.
@ast
Response to imatinib plus sirolimus in advanced chordoma.
@en
type
label
Response to imatinib plus sirolimus in advanced chordoma.
@ast
Response to imatinib plus sirolimus in advanced chordoma.
@en
prefLabel
Response to imatinib plus sirolimus in advanced chordoma.
@ast
Response to imatinib plus sirolimus in advanced chordoma.
@en
P2093
P50
P356
P1433
P1476
Response to imatinib plus sirolimus in advanced chordoma
@en
P2093
P304
P356
10.1093/ANNONC/MDP210
P50
P577
2009-07-01T00:00:00Z